Matthias Heinzel, CEO of life science at Merck KGaA

Mer­ck KGaA’s Mil­li­pore­Sig­ma in­vests $286M to build out biosafe­ty test­ing

Mil­li­pore­Sig­ma, the US and Cana­di­an life sci­ence di­vi­sion of Mer­ck KGaA, is plunk­ing down al­most $300 mil­lion to boost biosafe­ty test­ing in the US.

The com­pa­ny said it will in­vest $286 mil­lion to bulk up biosafe­ty test­ing at its man­u­fac­tur­ing site in Rockville, MD. The new, 250,000-square-foot fa­cil­i­ty ex­pan­sion will ex­tend its ca­pac­i­ty for biosafe­ty test­ing, an­a­lyt­i­cal de­vel­op­ment, vi­ral clear­ance suites and ser­vices for cell bank man­u­fac­tur­ing. Mil­li­pore­Sig­ma didn’t de­tail project time­line in its an­nounce­ment and did not re­spond­ed to a re­quest for com­ment from End­points News by press time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.